title: Population distribution of aldehyde dehydrogenase-2 genetic polymorphism: implications for risk assessment.
abstract: The role of genetic polymorphisms in modulating xenobiotic metabolism and susceptibility to cancer and other health effects has been suggested in numerous studies. However, risk assessments have generally not used this information to characterize population variability or adjust risks for susceptible subgroups. This paper focuses upon the aldehyde dehydrogenase-2 (ALDH2) system because it exemplifies the pivotal role genetic polymorphisms can play in determining enzyme function and susceptibility. Allelic variants in ALDH2 cause decreased ability to clear acetaldehyde and other aldehyde substrates, with homozygous variants (ALDH2*2/2) having no activity and heterozygotes (ALDH2*1/2) having intermediate activity relative to the predominant wild type (ALDH2*1/1). These polymorphisms are associated with increased buildup of acetaldehyde following ethanol ingestion and increased immediate symptoms (flushing syndrome) and long-term cancer risks. We have used Monte Carlo simulation to characterize the population distribution of ALDH2 allelic variants and inter-individual variability in aldehyde internal dose. The nonfunctional allele is rare in most populations, but is common in Asians such that 40% are heterozygotes and 5% are homozygote variants. The ratio of the 95th or 99th percentiles of the Asian population compared to the median of the U.S. population is 14- to 26-fold, a variability factor that is larger than the default pharmacokinetic uncertainty factor (3.2-fold) commonly used in risk assessment. Approaches are described for using ALDH2 population distributions in physiologically based pharmacokinetic-Monte Carlo refinements of risk assessments for xenobiotics which are metabolized to aldehyde intermediates (e.g., ethanol, toluene, ethylene glycol monomethyl ether).
authors.affiliation: Connecticut Department of Public Health, Hartford, 06134, USA. gary.ginsberg@po.state.ct.us
authors.forename: Gary
authors.initials: G
authors.lastname: Ginsberg
authors.forename: Susan
authors.initials: S
authors.lastname: Smolenski
authors.forename: Dale
authors.initials: D
authors.lastname: Hattis
authors.forename: Babasaheb
authors.initials: B
authors.lastname: Sonawane
mesh_terms: D000444:Aldehyde Dehydrogenase / Q000235:genetics* / Q000494:pharmacology*; D000071396:Aldehyde Dehydrogenase, Mitochondrial; D001208:Asia; D005828:Genetics, Population; D006801:Humans; D008962:Models, Theoretical; D009010:Monte Carlo Method; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D015262:Xenobiotics / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D015262:Xenobiotics; C096127:ALDH2 protein, human; D000444:Aldehyde Dehydrogenase; D000071396:Aldehyde Dehydrogenase, Mitochondrial